The central $3.13 target is the average of four individually verified analyst price targets, a low-to-high range of $3.00 to $3.50. Maxim Group's Naz Rahman reiterated a Buy with a $3.00 target on Nov. 14, 2026, and H.C. Wainwright's Brandon Folkes reiterated Buy at $3.00 on Nov. 13, 2026. Alliance Global Partners maintained a $3.50 target in May 2026, while Westpark Capital initiated coverage at $3.00 in April 2026. All four are Buy ratings, so the "analyst consensus" leans bullish despite the very wide gap between price and target. The $3.13 figure is a calculated mean, not a formal published consensus, and reflects the stock's deep-value, pre-approval status rather than any near-term earnings momentum. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
With the latest verified price near $0.79 and a 52-week range of roughly $0.69 to $1.57, reaching $3.13 would require a gain of about 299%, a very large move for any equity and an exceptional one for a pre-revenue biopharmaceutical. The path is almost entirely event-driven. Talphera has asked the FDA for a "Sprint Meeting" to discuss closing enrollment in its NEPHRO CRRT registrational study by Dec. 31, 2026, even if the original 70-patient target is not fully met, citing that the study remains over 80% powered for its primary endpoint. Topline data would follow roughly four to six weeks after enrollment closes, with a potential PMA submission and approval targeted for 2027.
Talphera has raised its estimate of Niyad's peak annual U.S. sales in CRRT to more than $200 million, citing quantitative physician research. Niyad holds FDA Breakthrough Device Designation, and management has flagged supportive industry developments, including updated KDIGO (Kidney Disease: Improving Global Outcomes) draft guidelines that elevate nafamostat as an alternative anticoagulant, and a New England Journal of Medicine study favoring CRRT over intermittent hemodialysis. A $14.2 million cash balance with no debt, plus roughly $16 million in conditional financing tranches, is expected to fund the program toward a potential approval.
The risks are substantial. Enrollment in the NEPHRO CRRT study has slowed sharply, with management reporting an 85%–90% drop in consented patients versus the prior-year period. If the FDA declines the early-closure request, enrollment would continue toward 70 patients, potentially delaying topline data and the PMA timeline. The company also plans to file a new Form S-3 shelf registration, a signal of possible future dilution. As a pre-revenue company with a market capitalization near $40 million and quarterly operating losses of roughly $4 million, any regulatory setback could pressure the share price materially.
The shares have been consolidating in a broad range, with the 52-week low near $0.69 acting as a key support level and the year's high near $1.57 serving as overhead resistance. A decisive move above the $1.00 psychological level would be an early sign of improving structure, while the $1.50 area represents the next meaningful resistance zone before any attempt on higher levels. Given the thin trading and event-driven nature of the stock, technical levels are secondary to regulatory catalysts. From what I see, combining this with AI-driven pattern tools helps keep the focus on the bigger picture.
Analyst price targets generally reflect a roughly 12-month horizon, though for Talphera they are effectively tied to the clinical and regulatory timeline rather than earnings. The most important near-term items are the FDA's response to the Sprint Meeting request, expected before year-end, followed by NEPHRO CRRT topline data, the closure of conditional financing tranches, and any update on the PMA filing. Investors should also watch the cash runway, enrollment commentary, and any new shelf-registration or equity financing activity. I’m watching this closely as the regulatory updates unfold.
For traders who want a more systematic view of shifting conditions, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening allows. For a volatile, event-driven name like TLPH, combining AI-generated signals with fundamental and regulatory research can add a useful layer of discipline to the decision process. In my view, this has become a regular part of how I cross-check ideas before making any moves.
The $3.13 stock price target is a calculated average of four Buy-rated analyst targets spanning $3.00 to $3.50, and it sits roughly 299% above the latest price. Reaching it depends almost entirely on the FDA allowing an early close of the NEPHRO CRRT study, favorable topline data, and a successful PMA filing and approval in 2027. The bullish case is grounded in Niyad's Breakthrough Device Designation, an expanded $200 million-plus peak sales estimate, and supportive guidelines and clinical literature. The bearish case rests on slowing enrollment, financing and dilution risk, and the binary nature of regulatory outcomes. There is no guarantee the stock approaches, reaches, or sustains that level; investors should monitor FDA feedback and topline data as the decisive catalysts.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
TLPH saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In 85 of the 88 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TLPH turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 42 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TLPH entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLPH advanced for three days, in 179 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
TLPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. TLPH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.783) is normal, around the industry mean (6.379). P/E Ratio (-4.565) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (1250.000) is also within normal values, averaging (183.387).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of innovative therapies for the treatment of acute and breakthrough pain
Industry PharmaceuticalsGeneric